Magazine Article | April 6, 2018

Companies To Watch: CytoDyn

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Phase 3 monoclonal to block HIV from infecting T cells, and earlier hopefuls.

SNAPSHOT
CytoDyn is in late-stage development of its lead drug, PRO 140 (leronlimab) for treating HIV infection as a unique CCR5-blocking monoclonal agent in the new class of “viral-entry” inhibitors. PRO 140 has just completed and announced positive data from a Phase 2b/3 clinical trial in combination with existing anti-HIV therapies and will produce data from its Phase 3 monotherapy trial later this year. It also is in a Phase 2 trial in prevention of graft-versus-host disease (GVHD). The company has other products and indications in development at earlier stages in its pipeline.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: